Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models - PubMed
5 hours ago
- #stem cell research
- #leukemia treatment
- #CAR-NK therapy
- Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease (MRD) and prevents relapse in leukemia models.
- Organoid culture system used to generate abundant induced NK lineage-committed progenitor (iNKP) cells.
- Engineered iNKP cells express CXCR4 and CARs, enabling migration to bone marrow and persistence for over 80 days.
- CAR-iNKP cell infusion protected animals from tumor challenges and reduced MRD post-chemotherapy.
- Single low-dose CAR-iNKP infusion prevented relapse in CD19+ B-ALL and CD7+ T-ALL models.
- Therapy addresses limitations of traditional CAR-NK cell infusion, offering a new strategy for cancer treatment.